Inflammation, cancer and chemoresistance: Taking advantage of the toll-like receptor signaling pathway

被引:141
作者
Chen, Rui
Alvero, Ayesha B.
Silasi, Dan-Arin
Mor, Gil
机构
[1] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Reprod Immunol Unit, New Haven, CT 06520 USA
[2] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA
关键词
chemokines; chemoresistance; epithelial ovarian cancer; MyD88; paclitaxel; Toll-like receptor;
D O I
10.1111/j.1600-0897.2006.00441.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The association between chronic inflammation and cancer has long been observed. Furthermore, NF-kappa B activation and the subsequent production of cytokines, chemokines, growth factors, and antiapoptotic proteins has been found to be involved in cancer progression and chemoresistance. However, the signals inducing NF-kappa B in cancer cells are still not well understood. Here, we reviewed the association between chronic inflammation and cancer, the role of NF-kappa B and its inhibitors as potential anticancer drugs, and Toll-like receptors as possible signal initiators for NF-kappa B activation and inflammation-induced carcinogenesis and chemoresistance. Furthermore, we propose that, the stimulation of Toll-like receptors by microbial components and/or endogenous ligands may represent the initial signal promoting a proinflammatory environment that will enhance tumor growth and chemoresistance.
引用
收藏
页码:93 / 107
页数:15
相关论文
共 109 条
[61]   Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex [J].
May, MJ ;
D'Acquisto, F ;
Madge, LA ;
Glöckner, J ;
Pober, JS ;
Ghosh, S .
SCIENCE, 2000, 289 (5484) :1550-1554
[62]  
Menard S, 1997, CLIN CANCER RES, V3, P817
[63]   Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis [J].
Moore, RJ ;
Owens, DM ;
Stamp, G ;
Arnott, C ;
Burke, F ;
East, N ;
Holdsworth, H ;
Turner, L ;
Rollins, B ;
Pasparakis, M ;
Kollias, G ;
Balkwill, F .
NATURE MEDICINE, 1999, 5 (07) :828-831
[64]   Macrophages, estrogen and the microenvironment of breast cancer [J].
Mor, G ;
Yue, W ;
Santen, RJ ;
Gutierrez, L ;
Eliza, M ;
Berstein, LM ;
Harada, N ;
Wang, JP ;
Lysiak, J ;
Diano, S ;
Naftolin, F .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1998, 67 (5-6) :403-411
[65]   IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling [J].
Muzio, M ;
Ni, J ;
Feng, P ;
Dixit, VM .
SCIENCE, 1997, 278 (5343) :1612-1615
[66]   Nuclear factor-κB inhibitors as sensitizers to anticancer drugs [J].
Nakanishi, C ;
Toi, M .
NATURE REVIEWS CANCER, 2005, 5 (04) :297-309
[67]   Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway [J].
Nguyen, DM ;
Chen, GA ;
Reddy, R ;
Tsai, W ;
Schrump, WD ;
Cole, G ;
Schrump, DS .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 127 (02) :365-375
[68]   Tissue-specific mRNA expression profiles of human toll-like receptors and related genes [J].
Nishimura, M ;
Naito, S .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (05) :886-892
[69]   TUMOR NECROSIS FACTOR [J].
OLD, LJ .
SCIENTIFIC AMERICAN, 1988, 258 (05) :59-&
[70]   Activators and target genes of Rel/NF-κB transcription factors [J].
Pahl, HL .
ONCOGENE, 1999, 18 (49) :6853-6866